Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Cecconetto L, Sarti S, Pietri E, Nanni O, Amadori D. Rocca A, et al. Among authors: maltoni r. Cancer Chemother Pharmacol. 2010 Apr;65(5):871-6. doi: 10.1007/s00280-009-1092-8. Epub 2009 Aug 20. Cancer Chemother Pharmacol. 2010. PMID: 19693503 Clinical Trial.
EAP in advanced gastric cancer.
Ridolfi R, Giunchi DC, Amadori M, Innocenti MP, Maltoni R, Amadori D. Ridolfi R, et al. Among authors: maltoni r. Eur J Cancer. 1993;29A(8):1219-20. doi: 10.1016/s0959-8049(05)80331-4. Eur J Cancer. 1993. PMID: 8518041 No abstract available.
Liver metastases from gastric carcinoma: report of a patient treated with adoptive immunotherapy (tumor-infiltrating lymphocytes plus interleukin-2 and subsequently local-regional lymphokine-activated killer cells plus interleukin-2).
Fabbri L, Ridolfi R, Riccobon A, Maltoni R, Flamini E, Fedriga R, Flamigni A, Migliori G, Ortolani F, Calzolari F, et al. Fabbri L, et al. Among authors: maltoni r. Tumori. 1995 Nov-Dec;81(6):445-9. doi: 10.1177/030089169508100613. Tumori. 1995. PMID: 8804474
Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R, Flamini E, Riccobon A, De Paola F, Maltoni R, Gardini A, Ridolfi L, Medri L, Poletti G, Amadori D. Ridolfi R, et al. Among authors: maltoni r. Cancer Immunol Immunother. 1998 Jun;46(4):185-93. doi: 10.1007/s002620050477. Cancer Immunol Immunother. 1998. PMID: 9671141 Free PMC article.
84 results